3ln4 › Citations

The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family.

Bade-Döding C, Theodossis A, Gras S, Kjer-Nielsen L, Eiz-Vesper B, Seltsam A, Huyton T, Rossjohn J, McCluskey J, Blasczyk R
Haematologica 96 110-8 (2011)
Cited: 43 times
EuropePMC logo PMID: 20934997

Abstract

Background

Polymorphic differences between human leukocyte antigen (HLA) molecules affect the specificity and conformation of their bound peptides and lead to differential selection of the T-cell repertoire. Mismatching during allogeneic transplantation can, therefore, lead to immunological reactions.

Results

Peptide analysis revealed that all B*41 alleles have an identical anchor motif at peptide position 2 (glutamic acid), but differ in their choice of C-terminal pΩ anchor (proline, valine, leucine). Additionally, B*41:04 displayed a greater preference for long peptides (>10 residues) when compared to the other B*41 allomorphs, while the longest peptide to be eluted from the allelic group (a 16mer) was obtained from B*41:03. The crystal structures of HLA-B*41:03 and HLA-B*41:04 revealed that both alleles interact in a highly conserved manner with the terminal regions of their respective ligands, while micropolymorphism-induced changes in the steric and electrostatic properties of the antigen-binding cleft account for differences in peptide repertoire and auxiliary anchoring.

Conclusion

Differences in peptide repertoire, and peptide length specificity reflect the significant functional evolution of these closely related allotypes and signal their importance in allogeneic transplantation, especially B*41:03 and B*41:04, which accommodate longer peptides, creating structurally distinct peptide-HLA complexes.

Articles - 3ln4 mentioned but not cited (9)

  1. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, Lieberman JA, Daly MJ, Sullivan PF. Nat Commun 5 4757 (2014)
  2. The molecular basis for Mucosal-Associated Invariant T cell recognition of MR1 proteins. López-Sagaseta J, Dulberger CL, Crooks JE, Parks CD, Luoma AM, McFedries A, Van Rhijn I, Saghatelian A, Adams EJ. Proc Natl Acad Sci U S A 110 E1771-8 (2013)
  3. The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family. Bade-Döding C, Theodossis A, Gras S, Kjer-Nielsen L, Eiz-Vesper B, Seltsam A, Huyton T, Rossjohn J, McCluskey J, Blasczyk R. Haematologica 96 110-118 (2011)
  4. Evolution and comparative analysis of the bat MHC-I region. Ng JH, Tachedjian M, Deakin J, Wynne JW, Cui J, Haring V, Broz I, Chen H, Belov K, Wang LF, Baker ML. Sci Rep 6 21256 (2016)
  5. Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. Luo H, Du T, Zhou P, Yang L, Mei H, Ng H, Zhang W, Shu M, Tong W, Shi L, Mendrick DL, Hong H. Comb Chem High Throughput Screen 18 296-304 (2015)
  6. Predicting Humoral Alloimmunity from Differences in Donor and Recipient HLA Surface Electrostatic Potential. Mallon DH, Kling C, Robb M, Ellinghaus E, Bradley JA, Taylor CJ, Kabelitz D, Kosmoliaptsis V. J Immunol 201 3780-3792 (2018)
  7. Structural Comparison Between MHC Classes I and II; in Evolution, a Class-II-Like Molecule Probably Came First. Wu Y, Zhang N, Hashimoto K, Xia C, Dijkstra JM. Front Immunol 12 621153 (2021)
  8. The Structure of a Peptide-Loaded Shark MHC Class I Molecule Reveals Features of the Binding between β2-Microglobulin and H Chain Conserved in Evolution. Wu Y, Zhang N, Wei X, Lu S, Li S, Hashimoto K, Dijkstra JM, Xia C. J Immunol 207 308-321 (2021)
  9. Bioinformatics pipeline unveils genetic variability to synthetic vaccine design for Indian SARS-CoV-2 genomes. Ghosh N, Saha I, Sharma N, Nandi S. Int Immunopharmacol 112 109224 (2022)


Reviews citing this publication (5)

  1. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Front Immunol 8 292 (2017)
  2. Human leukocyte antigen-associated drug hypersensitivity. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Curr Opin Immunol 25 81-89 (2013)
  3. HLA-E: a novel player for histocompatibility. Kraemer T, Blasczyk R, Bade-Doeding C. J Immunol Res 2014 352160 (2014)
  4. Human leukocyte antigen and idiosyncratic adverse drug reactions. Usui T, Naisbitt DJ. Drug Metab Pharmacokinet 32 21-30 (2017)
  5. Bioinformatic databases and resources in the public domain to aid HLA research. Helmberg W. Tissue Antigens 80 295-304 (2012)

Articles citing this publication (29)

  1. HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control. Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews PC, Chen F, Riddell L, Walker BD, Ndung'u T, Buus S, Goulder P. J Virol 86 919-929 (2012)
  2. Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. Narzi D, Becker CM, Fiorillo MT, Uchanska-Ziegler B, Ziegler A, Böckmann RA. J Mol Biol 415 429-442 (2012)
  3. Naturally processed non-canonical HLA-A*02:01 presented peptides. Hassan C, Chabrol E, Jahn L, Kester MG, de Ru AH, Drijfhout JW, Rossjohn J, Falkenburg JH, Heemskerk MH, Gras S, van Veelen PA. J Biol Chem 290 2593-2603 (2015)
  4. The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch. Celik AA, Kraemer T, Huyton T, Blasczyk R, Bade-Döding C. Immunogenetics 68 29-41 (2016)
  5. HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response-Implications on HSCT Outcome. Kraemer T, Celik AA, Huyton T, Kunze-Schumacher H, Blasczyk R, Bade-Döding C. Stem Cells Int 2015 346714 (2015)
  6. Highly divergent T-cell receptor binding modes underlie specific recognition of a bulged viral peptide bound to a human leukocyte antigen class I molecule. Liu YC, Miles JJ, Neller MA, Gostick E, Price DA, Purcell AW, McCluskey J, Burrows SR, Rossjohn J, Gras S. J Biol Chem 288 15442-15454 (2013)
  7. Association between HLA class I and class II alleles and the outcome of West Nile virus infection: an exploratory study. Lanteri MC, Kaidarova Z, Peterson T, Cate S, Custer B, Wu S, Agapova M, Law JP, Bielawny T, Plummer F, Tobler LH, Loeb M, Busch MP, Bramson J, Luo M, Norris PJ. PLoS One 6 e22948 (2011)
  8. Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. Chan KF, Gully BS, Gras S, Beringer DX, Kjer-Nielsen L, Cebon J, McCluskey J, Chen W, Rossjohn J. Nat Commun 9 1026 (2018)
  9. The energetic basis underpinning T-cell receptor recognition of a super-bulged peptide bound to a major histocompatibility complex class I molecule. Liu YC, Chen Z, Burrows SR, Purcell AW, McCluskey J, Rossjohn J, Gras S. J Biol Chem 287 12267-12276 (2012)
  10. Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue. Marcilla M, Alpízar A, Lombardía M, Ramos-Fernandez A, Ramos M, Albar JP. Mol Cell Proteomics 13 462-474 (2014)
  11. Novel HLA class I associations with HIV-1 control in a unique genetically admixed population. Valenzuela-Ponce H, Alva-Hernández S, Garrido-Rodríguez D, Soto-Nava M, García-Téllez T, Escamilla-Gómez T, García-Morales C, Quiroz-Morales VS, Tapia-Trejo D, Del Arenal-Sánchez S, Prado-Galbarro FJ, Hernández-Juan R, Rodríguez-Aguirre E, Murakami-Ogasawara A, Mejía-Villatoro C, Escobar-Urias IY, Pinzón-Meza R, Pascale JM, Zaldivar Y, Porras-Cortés G, Quant-Durán C, Lorenzana I, Meza RI, Palou EY, Manzanero M, Cedillos RA, Aláez C, Brockman MA, Harrigan PR, Brumme CJ, Brumme ZL, Ávila-Ríos S, Reyes-Terán G, Mesoamerican HIV Project Group. Sci Rep 8 6111 (2018)
  12. ERAP1 enzyme-mediated trimming and structural analyses of MHC I-bound precursor peptides yield novel insights into antigen processing and presentation. Li L, Batliwala M, Bouvier M. J Biol Chem 294 18534-18544 (2019)
  13. Pocketcheck: updating the HLA class I peptide specificity roadmap. Huyton T, Ladas N, Schumacher H, Blasczyk R, Bade-Doeding C. Tissue Antigens 80 239-248 (2012)
  14. Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches. Kunze-Schumacher H, Blasczyk R, Bade-Doeding C. J Immunol Res 2014 246171 (2014)
  15. Tapasin facilitation of natural HLA-A and -B allomorphs is strongly influenced by peptide length, depends on stability, and separates closely related allomorphs. Geironson L, Thuring C, Harndahl M, Rasmussen M, Buus S, Røder G, Paulsson KM. J Immunol 191 3939-3947 (2013)
  16. The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. Saunders PM, MacLachlan BJ, Pymm P, Illing PT, Deng Y, Wong SC, Oates CVL, Purcell AW, Rossjohn J, Vivian JP, Brooks AG. Proc Natl Acad Sci U S A 117 11636-11647 (2020)
  17. Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02. Simper GS, Hò GT, Celik AA, Huyton T, Kuhn J, Kunze-Schumacher H, Blasczyk R, Bade-Döding C. J Immunol Res 2018 5086503 (2018)
  18. A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes. Badrinath S, Kunze-Schumacher H, Blasczyk R, Huyton T, Bade-Doeding C. J Immunol Res 2014 298145 (2014)
  19. HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues. Hò GT, Heinen FJ, Huyton T, Blasczyk R, Bade-Döding C. Immunogenetics 71 353-360 (2019)
  20. Position 45 influences the peptide binding motif of HLA-B*44:08. Badrinath S, Huyton T, Schumacher H, Blasczyk R, Bade-Doeding C. Immunogenetics 64 245-249 (2012)
  21. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Kacen A, Javitt A, Kramer MP, Morgenstern D, Tsaban T, Shmueli MD, Teo GC, da Veiga Leprevost F, Barnea E, Yu F, Admon A, Eisenbach L, Samuels Y, Schueler-Furman O, Levin Y, Nesvizhskii AI, Merbl Y. Nat Biotechnol 41 239-251 (2023)
  22. The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity. Simper GS, Gräser LS, Celik AA, Kuhn J, Kunze-Schumacher H, Hò GT, Blasczyk R, Pich A, Bade-Doeding C. Pharmaceutics 11 E536 (2019)
  23. Dual non-contiguous peptide occupancy of HLA class I evoke antiviral human CD8 T cell response and form neo-epitopes with self-antigens. Xiao Z, Ye Z, Tadwal VS, Shen M, Ren EC. Sci Rep 7 5072 (2017)
  24. Releasing the concept of HLA-allele specific peptide anchors in viral infections: A non-canonical naturally presented human cytomegalovirus-derived HLA-A*24:02 restricted peptide drives exquisite immunogenicity. Pump WC, Schulz R, Huyton T, Kunze-Schumacher H, Martens J, Hò GT, Blasczyk R, Bade-Doeding C. HLA 94 25-38 (2019)
  25. Unravelling the Proteomics of HLA-B*57:01+ Antigen Presenting Cells during Abacavir Medication. Haukamp FJ, Gall E, Hò GT, Hiemisch W, Stieglitz F, Kuhn J, Blasczyk R, Pich A, Bade-Döding C. J Pers Med 12 40 (2022)
  26. Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects. Gall E, Stieglitz F, Pich A, Behrens GMN, Kuhn J, Blasczyk R, Haukamp FJ, Bade-Döding C. Biomedicines 10 693 (2022)
  27. The polymorphism at residue 156 determines the HLA-B*35 restricted peptide repertoire during HCMV infection. Abels WC, Manandhar T, Kunze-Schumacher H, Blasczyk R, Bade-Döding C. Immunogenetics 70 639-646 (2018)
  28. Crystal structure of suboptimal viral fragments of Epstein Barr Virus Rta peptide-HLA complex that stimulate CD8 T cell response. Huan X, Zhuo Z, Xiao Z, Ren EC. Sci Rep 9 16660 (2019)
  29. Epitope length variants balance protective immune responses and viral escape in HIV-1 infection. Pymm P, Tenzer S, Wee E, Weimershaus M, Burgevin A, Kollnberger S, Gerstoft J, Josephs TM, Ladell K, McLaren JE, Appay V, Price DA, Fugger L, Bell JI, Schild H, van Endert P, Harkiolaki M, Iversen AKN. Cell Rep 38 110449 (2022)


Quick links